To date, TRPV1 agonist, capsaicin or resiniferatoxin, and antagonists such as capsazepine (CPZ), BCTC, SB-705498, or NEO6860 were tested to treat migraine, osteoarthritis, overactive bladder, atopic dermatitis, and neuropathic pain (clinicaltrials.gov). This evidence concerns the gene TRPV1 and atopic eczema.